You are here: Home > Prescription(RX) Drugs > U > Ulesfia (Shionogi Pharma, Inc.)|
benzyl alcohol lotion
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
Ulesfia Lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
1.3 Adjunctive Measures
Ulesfia Lotion should be used in the context of an overall lice management program:
2 DOSAGE AND ADMINISTRATION
Ulesfia Lotion is not for oral, ophthalmic, or intravaginal use.
Using the guideline in Table1, apply sufficient Ulesfia Lotion to dry hair to completely saturate the scalp and hair; leave on for 10 minutes, then thoroughly rinse off with water. Repeat treatment after 7 days. Avoid contact with eyes.
Table 1: Ulesfia Lotion Usage Guideline
3 DOSAGE FORM AND STRENGTH
Ulesfia Lotion is a white topical lotion containing benzyl alcohol, 5% (50 mg/g of lotion).
5 WARNINGS AND PRECAUTIONS
5.1 Neonatal Toxicity
Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants. Neonates (i.e. patients less than 1 month of age or preterm infants with a corrected age of less than 44 weeks) could be at risk for gasping syndrome if treated with Ulesfia Lotion [see Use in Specific Populations (8.4)].
5.2 Eye Irritation
Avoid eye exposure. Ulesfia Lotion may cause eye irritation. If Ulesfia Lotion comes in contact with the eyes, flush them immediately with water. If irritation persists, consult a physician.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The rates of adverse reactions below were derived from two randomized, multi-center, vehicle-controlled clinical trials and one open-label study in subjects with head lice infestation.
Skin, scalp, and ocular irritation were monitored in the clinical trials. All subjects were queried about the presence of skin and scalp symptoms; the results are presented in Table 2.
The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.
Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category B
There are no adequate and well-controlled studies with topical benzyl alcohol in pregnant women. Reproduction studies conducted in rats and rabbits were negative. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
No comparisons of animal exposure with human exposure are provided in this labeling due to the low systemic exposure noted in the clinical pharmacokinetic study [see Clinical Pharmacology (12.3)] which did not allow for the determination of human AUC values that could be used for this calculation.
Pregnant rats were dosed with benzyl alcohol via subcutaneous injection at 100, 250, and 500 mg/kg/day. No teratogenic effects were noted at any dose. Maternal toxicity and decreased fetal weight occurred at 500 mg/kg/day. When pregnant rabbits received subcutaneous injections of benzyl alcohol at 100, 250, and 400 mg/kg/day, there were no teratogenic effects in offspring at any dose. In rabbits, maternal toxicity occurred at the two higher doses and was associated with decreased fetal weight at the highest dose.
8.3 Nursing Mothers
It is not known whether benzyl alcohol is excreted into human milk. Because some systemic absorption of topical benzyl alcohol may occur and because many drugs are excreted in human milk, caution should be exercised when Ulesfia Lotion is administered to a nursing woman.
8.4 Pediatric Use
The safety and effectiveness of Ulesfia Lotion was evaluated in two multicenter, randomized, double-blind, vehicle-controlled studies which were conducted in 628 subjects 6 months of age and older with active head lice infestation [see Clinical Studies (14)].
Rates of adverse events in younger children (6 months to 12 years) were similar to those of older children and adults.
Safety in pediatric patients below the age of 6 months has not been established. Ulesfia Lotion is not recommended in pediatric patients under six months of age because of the potential for increased systemic absorption due to a high ratio of skin surface area to body mass and the potential for an immature skin barrier.
Neonates could be at risk for gasping syndrome if treated with Ulesfia Lotion [see Warnings and Precautions (5.1)].
Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome. The gasping syndrome (characterized by central nervous depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages > 99 mg/kg/day in preterm neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hemotologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although expected systemic exposure of benzyl alcohol from proper use of Ulesfia Lotion is substantially lower than those reported in association with the gasping syndrome, the minimum amount of benzyl alcohol at which toxicity may occur is not known.
Ulesfia (benzyl alcohol) Lotion is supplied as a white topical lotion containing benzyl alcohol, 5%. Inactive ingredients in this formulation are water, mineral oil, sorbitan monooleate, polysorbate 80, carbomer 934P and trolamine.
The active ingredient, benzyl alcohol, is a clear, colorless liquid with a mild aromatic odor. Benzyl alcohol has a molecular mass of 108.14 g/mol. The molecular formula is C7H8O.
The chemical structure of benzyl alcohol is
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
In vitro studies of the effect of Ulesfia Lotion on native, captured lice suggest that benzyl alcohol inhibits lice from closing their respiratory spiracles, allowing the vehicle to obstruct the spiracles and causing the lice to asphyxiate.
The absorption of benzyl alcohol from Ulesfia Lotion was evaluated in 19 subjects with head lice infestation. Subjects were divided into two age groups: 6 months to 3 years and 4 to 11 years. Ulesfia Lotion was applied for an exaggerated exposure period (3 times the normal exposure period). Benzyl alcohol was quantified in a single plasma sample in 4 out of 19 subjects (21%): three subjects in the 6 months to 3 years age group at 0.5 hour post-treatment (ranging from 1.97 to 2.99 mcg/mL) and one subject in the 4 to 11 year age group (1.63 mcg/mL) at 1 hour post-treatment out of a total of 102 samples analyzed.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals to evaluate carcinogenic potential of Ulesfia Lotion have not been conducted. No evidence of carcinogenic activity was noted for benzyl alcohol in 2 year oral carcinogenicity studies in rats (doses up to 400 mg/kg benzyl alcohol) or mice (doses up to 200 mg/kg benzyl alcohol) conducted by the National Toxicology Program.
Benzyl alcohol has produced mixed results in genetic testing. Benzyl alcohol was negative in the Ames test with and without metabolic activation, sex-linked recessive lethal assay, and a replicative DNA synthesis assay (conducted in male rats). Negative results were obtained in the mouse lymphoma assay with metabolic activation, but a positive response was noted in the mouse lymphoma assay without metabolic activation at a concentration producing a high level of cellular toxicity. Benzyl alcohol was positive in the Chinese hamster ovary chromosomal aberration assay with metabolic activation.
No fertility studies have been conducted with benzyl alcohol.
14 CLINICAL STUDIES
Two multicenter, randomized, double-blind, vehicle-controlled studies were conducted in 628 subjects 6 months of age and older with active head lice infestation. For the evaluation of efficacy, the youngest subject from each household was enrolled in the Primary Treatment Cohort with Ulesfia Lotion or vehicle. Other infested household members were enrolled in a Secondary Treatment Cohort and received the same treatment as the youngest subjects. The Secondary Treatment Cohort was not included in the efficacy analysis, but was evaluated for all safety parameters.
In Study One, 125 Primary Treatment Cohort Subjects were randomized to Ulesfia Lotion (N=63) and vehicle (N=62). Study Two enrolled 125 Primary Treatment Cohort Subjects: 64 randomized to Ulesfia Lotion and 61 to vehicle. Treatment was applied two times separated by one week.
Efficacy was assessed as the proportion of subjects who were free of live lice 14 days after the final treatment. Subjects with live lice present at any time after first treatment were considered to be treatment failures. Table 4 contains the proportion of subjects who were free of live lice in each of the two trials.
16 HOW SUPPLIED/STORAGE AND HANDLING
Ulesfia Lotion is a white topical lotion containing benzyl alcohol, 5% (50 mg/g of lotion) supplied as 4 fl oz (113 g) (NDC 59630-780-04) or as 8 fl oz (227 g) (NDC 59630-780-08) in polypropylene bottles.
Store at 20º - 25º C (68º - 77º F); excursions permitted to 15º - 30º C (59º - 86º F) [See USP controlled room temperature].
Do not freeze. Keep out of reach of children.
17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information).
This medication is to be used as directed by the physician. Use only on scalp and scalp hair. Avoid contact with eyes. As with any topical medication, patients should wash hands after application.
Instruct patients on proper use of Ulesfia Lotion, including the amount to apply, how long to leave it on the hair, and the importance of a second treatment 1 week (7 days) after the initial application.
Inform patients that Ulesfia Lotion may cause eye irritation, skin irritation, and contact sensitization.
Instruct patients to inform a physician if the area of the application shows signs of irritation and any signs of adverse reactions.
Read the Patient Information that comes with Ulesfia Lotion before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment.
What is Ulesfia Lotion?
Ulesfia Lotion is a prescription medicine used to get rid of lice in scalp hair of children and adults.
It is not known if Ulesfia Lotion is safe for children under 6 months of age or in people over age 60.
Once Ulesfia Lotion is washed off, a fine-tooth comb may be used to remove treated lice and nits from the hair and scalp. All personal items exposed to the hair or lice should be washed in hot water or dry-cleaned. See "How do I stop the spread of lice?" at the end of this leaflet.
What should I tell my healthcare provider before I use Ulesfia Lotion?
Tell your healthcare provider if your baby was born early so your healthcare provider can decide if your infant is old enough for Ulesfia Lotion.
Before you use Ulesfia, tell your healthcare provider if you:
How should I use Ulesfia Lotion?
What are the possible side effects of Ulesfia Lotion?
People using Ulesfia Lotion may have skin or eye:
These are not all the side effects of Ulesfia Lotion. For more information, ask your healthcare provider.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Ulesfia Lotion?
Keep Ulesfia Lotion and all medicines out of the reach of children.
What are the ingredients in Ulesfia Lotion?
Active ingredient: benzyl alcohol, 5%
Inactive ingredients: purified water, mineral oil, sorbitan monooleate, polysorbate 80, carbomer 934P and trolamine
General Information about Ulesfia Lotion
Medicines are sometimes prescribed for conditions other than those described in the patient information leaflets. Do not use Ulesfia Lotion for any condition for which it was not prescribed by your healthcare provider. Do not give Ulesfia Lotion to other people, even if they have the same symptoms as you. It may harm them.
This leaflet summarizes the most important information about Ulesfia Lotion. If you would like more information, talk to your healthcare provider. You can also ask your healthcare provider for information about Ulesfia Lotion that is written for healthcare professionals.
Patient Instructions for Use
Apply the full amount of Ulesfia Lotion prescribed by your healthcare provider for each of your 2 treatments one week apart. Ulesfia Lotion gets rid of lice but does not get rid of lice eggs so a second treatment is needed one week (7 days) after the first treatment.
Ulesfia Lotion comes in a 4 oz. and 8 oz. bottle. For different hair lengths, use the following as a guide for the amount of Ulesfia Lotion you may need to cover the hair and scalp completely.
If not enough Ulesfia Lotion is used, some lice may escape treatment. It is important to use the full amount of Ulesfia Lotion prescribed by your doctor.
Correct application of Ulesfia Lotion
One week (7 days) after your first treatment, repeat the steps above to help get rid of lice that hatched from eggs.
How do I stop the spread of lice?
To help prevent the spread of lice from one person to another, here are some steps you can take.
This Patient Leaflet has been approved by the U.S. Food and Drug Administration.
BNZ-PI-13 Rev. 12/2010
PRINCIPAL DISPLAY PANEL - 227 g Bottle Carton
8 oz. (227 g)
For topical use on the scalp
SHIONOGI PHARMA, INC.
Ulesfia 8 oz Carton
Revised: 02/2011 Shionogi Pharma, Inc.
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2020
|Over-the-counter (OTC) Drugs|